Dermot F. McGinnity - Concepedia

Author

Dermot F. McGinnity

Also Known As

D F McGinnity, D. F. McGinnity, D.F. McGinnity, Dermot F. McGinnity, Dermot F. Mcginnity, Dermot Francis McGinnity, Dermot McGinnity

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)Loughborough University AstraZeneca (Singapore)AstraZeneca (Sweden)AstraZeneca (United States)

About

Dermot F. McGinnity is an author at AstraZeneca (United Kingdom) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	691
2	Biochemistry	7	7	458
3	Natural Sciences	3	3	91
4	Engineering	2	2	76
5	Biomolecular Engineering	1	1	48

Dermot F. McGinnity

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES Robert J. Riley, Dermot F. McGinnity, Rupert P. Austin Drug Metabolism and Disposition	2005	364
Epoxidation of olefins by cytochrome P450: Evidence from site-specific mutagenesis for hydroperoxo-iron as an electrophilic oxidant Alfin D. N. Vaz, Dermot F. McGinnity, Minor J. Coon Proceedings of the National Academy of Sciences	1998	290
EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCE Dermot F. McGinnity, Matthew G. Soars, Richard A. Urbanowicz, Drug Metabolism and Disposition	2004	268
From ATP to AZD6140: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis Brian Springthorpe, A. S. Bailey, Patrick Barton, Bioorganic & Medicinal Chemistry Letters ThrombosisPlatelet Aggregation InhibitorsBiochemistryBlood PlateletMedicine	2007	233
Automated Definition of the Enzymology of Drug Oxidation by the Major Human Drug Metabolizing Cytochrome P450s Dermot F. McGinnity, Alison J. Parker, Matthew G. Soars, Drug Metabolism and Disposition	2000	122
Evaluation of Human Pharmacokinetics, Therapeutic Dose and Exposure Predictions Using Marketed Oral Drugs Dermot F. McGinnity, John Collington, Rupert P. Austin, Current Drug Metabolism Marketed Oral DrugsPharmacodynamic ModelingTranslational MedicinePharmacological StudyBioanalysis	2007	122
Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist James S. Scott, Amber Balazs, Bernard Barlaam, Journal of Medicinal Chemistry	2020	109
EVALUATION OF TIME-DEPENDENT CYTOCHROME P450 INHIBITION USING CULTURED HUMAN HEPATOCYTES Dermot F. McGinnity, Amanda J. Berry, Jane R. Kenny, Drug Metabolism and Disposition	2006	99
Prediction of Human Renal Clearance from Preclinical Species for a Diverse Set of Drugs That Exhibit Both Active Secretion and Net Reabsorption Stuart W. Paine, Karelle Ménochet, Rebecca Denton, Drug Metabolism and Disposition	2011	97
Evaluation of Multiple in Vitro Systems for Assessment of CYP3A4 Induction in Drug Discovery: Human Hepatocytes, Pregnane X Receptor Reporter Gene, and Fa2N-4 and HepaRG Cells Dermot F. McGinnity, George Zhang, Jane R. Kenny, Drug Metabolism and Disposition	2009	88

Page 1